Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH +0.34%73 Receivables Turnover is 1.55 as of Mar. 2026. GuruFocus rates SOPH with a GF Score™ of 73/100 and a GF Value™ of $5.07 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 660 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 52.73% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sophia Genetics's Revenue for the
three
months ended in Mar. 2026 was $21.69 Mil. Sophia Genetics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $13.97 Mil.
Hence, Sophia Genetics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.55.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sophia Genetics Receivables Turnover Related Terms
Sophia Genetics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOPH vs WEAV, NRC, MDRX: Receivables Turnover Comparison
For the Health Information Services subindustry, Sophia Genetics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Receivables Turnover of 1.55 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #348 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 52.7%.
Is Sophia Genetics' Receivables Turnover too high?
Sophia Genetics' current Receivables Turnover is 1.55. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. Sophia Genetics' value of 1.55 is 80% below this industry median. Based on the distribution chart, Sophia Genetics ranks #348 out of 660 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Receivables Turnover compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #348 out of 660 companies for Receivables Turnover. This places Sophia Genetics in the lower half of its industry. The industry median Receivables Turnover is 7.75. Sophia Genetics' value of 1.55 is 80% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Receivables Turnover of 1.55 is 80% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Receivables Turnover is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.07, compared to a current price of $5.87 — trading 15.8% above its estimated fair value. The current Receivables Turnover is 1.55 and 80% below the Healthcare Providers & Services industry median of 7.75. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Receivables Turnover is 1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.87 is trading 15.8% above its estimated GF Value™ of $5.07.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
Receivables Turnover: 1.55
GF Value™: $5.07 vs. price of $5.87 (15.8% above fair value)
Industry Position: 80% below the Healthcare Providers & Services median (#348 of 660)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score
Get the complete analysis for SOPH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
